Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Viral Safety by Design for Cell and Gene Therapy Products Mark Plavsic, Chief Technology Officer at Lysogene & Dr. Magali Roche, Sales Manager, PathoQuest, Biologics Genomic Service Presented by Mark Plavsic, Chief Technology Officer at Lysogene Together with product efficacy, product safety is an essential characteristic of any ... 2 years ago | 75 mins Viral Safety by Design for Cell and Gene Therapy Products Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologic... 3 years ago | 67 mins Viral Safety by Design for Cell and Gene Therapy Products Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologic... 4 years ago | 68 mins Upstream Viral Risk Mitigation Strategy for High Titer Biologics Manufacturing Aaron Mack, Engineer at Biogen & Dave Kolwyck, Director at Biogen and David Gemmell Senior Process Engineer at Merck Presented by Aaron Mack, Engineer at Biogen This talk will focus on the risk based approach that Biogen used for determining which raw materials to i... 3 years ago | 83 mins Qualification of Raw Materials and Cell Substrates for Biomanufacturing Maura Kibbey Senior Scientific Fellow, Global Biologics at USP and Martin Wisher, Global Head of Regulatory Affairs at Merck Presented by Maura C. Kibbey, Ph.D., Senior Scientific Fellow, Global Biologics U.S. Pharmacopeia Followed by an Industry Perspective presented by Mar... 3 years ago | 83 mins Qualification of Raw Materials and Cell Substrates for Biomanufacturing Maura Kibbey Senior Scientific Fellow, Global Biologics at USP and Martin Wisher, Global Head of Regulatory Affairs at Merck Presented by Maura C. Kibbey, Ph.D., Senior Scientific Fellow, Global Biologics U.S. Pharmacopeia Followed by an Industry Perspective presented by Mar... 3 years ago | 84 mins FDA Perspective on Aseptic Process Simulation for Cell Therapy Product Manufa... Dr Lily Koo, Consumer Safety Officer at FDA and Dr Keen Chung, Principal Scientist (Upstream Process) at Pall Biotech FDA Perspective on Aseptic Process Simulation for Cell Therapy Product Manufacturing Presented by Dr Lily Koo, Consumer Safety Officer at Food and Dru... 3 years ago | 82 mins FDA Perspective on Aseptic Process Simulation for Cell Therapy Product Manufa... Dr Lily Koo, Consumer Safety Officer at FDA and Dr Keen Chung, Principal Scientist (Upstream Process) at Pall Biotech FDA Perspective on Aseptic Process Simulation for Cell Therapy Product Manufacturing Presented by Dr Lily Koo, Consumer Safety Officer at Food and Dr... 3 years ago | 83 mins
